This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Breast Cancer  • Surgical Oncology  • Women's Health  • Women's Health, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We thank Dr Badruddoja for his keen comment and interest in our article. Tumor size was included in many staging systems as an independent predictor of survival. Multiple data sets demonstrate an excellent prognosis for node-negative, but 1-cm or less sized cancers.¹ In treating our patients, we sometimes see "borderline" tumor sizes close to 1 cm or 2 cm but not over. In these cases, clinicians have difficulty in deciding whether adjuvant chemotherapy is needed and what the true T stage of the patient is for prognosis. Accordingly, this study aims to figure out whether preoperative core-needle biopsy (CNB) may alter the T stage and affect the decision of adjuvant chemotherapy.

For stage I patients with negative axillary node registered at our institute, we carried out adjuvant chemotherapy when they had moderate- to high-risk problems. They met at least 1 requirement out of the following: tumor size over . . . [Full Text of this Article]

AUTHOR INFORMATION
Jung-Hyun Yang, MD, PhD, FACS

RELATED ARTICLE

Size of Breast Cancer Tumor After Core-Needle Biopsy and Fine-Needle Aspiration Does Not Affect Patient Treatment Plan
Mohammed Badruddoja
Arch Surg. 2005;140(10):1008-1009.
EXTRACT | FULL TEXT